B-Raf and the inhibitors: from bench to bedside

Table 2 B-Raf inhibitors in phase III clinical trials

Drugs/regimen	Diseases	Dosage	Clinical trial ID*
Dabrafenib	Advanced melanoma	Dabrafenib	NCT01682083
(GSK2118436)		150 mg BID	NCT01584648
+Trametinib (GSK1120212)		±Trametinib 2 mg OD for 12 months	NCT01597908
Vemurafenib (PLX4032)	Advanced melanoma	Vemurafenib 960 mg BID	NCT01597908
+ Dacarbazine		±Dacarbazine 1000 mg/m2 IV Q3weeks for 12 months	NCT01667419 NCT01689519
+ GDC-0973		± GDC-0973 60 mg QD for 21 of 28 days	NCT01006980
Sorafenib	Renal cell carcinoma	Sorafenib 400 mg BID	NCT00478114
+multiple combinations	Hepatocellular carcinoma	+multiple combinations	NCT01135056
	Acute myeloid leukemia		NCT01371981
	Stage III/IV melanoma		NCT00111007
	Non-small cell lung cancer		NCT00449033
	Pancreatic cancer		NCT00541021

ISSN: 1756-8722